Skip to main content Skip to search Skip to main navigation
Flask High Quality Molecules
Truck Fast Delivery
Award Trusted by Researchers
Follow us: LinkedIn Contact Security
Latest Insights & Research

News & Discoveries

Stay updated with the latest breakthroughs in medicinal chemistry, drug discovery, and scientific innovation from Activate Scientific.

Featured Articles

LinkedIn

Oxolanes deserve more credit in drug design conversations.

The humble tetrahydrofuran ring is one of the most reliable pieces of scaffolding in a medicinal chemist's toolkit, and it earns that reputation on real merit. This five-membered oxygen heterocycle sits in a useful middle ground. It is saturated enough to add real three-dimensionality to a molecule, and its ring oxygen provides a genuine hydrogen bond acceptor without adding basicity or excess polarity. That balance is likely why the oxolane keeps appearing in approved medicines rather than staying a synthetic chemistry curiosity. The ring also brings a quieter advantage: chemical robustness. Oxolane carries a ring strain of roughly 25 kJ/mol, far below the 106 kJ/mol of oxetane and the 112 kJ/mol of epoxides. That low strain means an oxolane substituent can sit inside a molecule through synthesis and metabolism without the ring-opening liabilities that come with its smaller, more reactive cousins, making it a dependable choice when incorporating an oxygen heterocycle. Also, compared to acyclic ethers, oxolanes provide a more conformationally defined scaffold, which can be advantageous when optimising ligand binding. Terazosin is a good example of how the scaffold can be used, a single tetrahydrofuran-2-yl group attached through a carbonyl to a piperazine ring. Marketed as Hytrin for hypertension and benign prostatic hyperplasia, it is one of thirteen FDA-approved drugs built around a THF core. Gemcitabine shows the same ring used in a completely different way. Instead of hanging off the side of the molecule, the oxolane is the core of the nucleoside itself. The two fluorine atoms influence the preferred sugar conformation and contribute to gemcitabine's unique biochemical properties, ultimately leading to masked chain termination after incorporation into DNA. It remains a standard treatment for pancreatic, non-small cell lung, and ovarian cancers. Are you building saturated oxygen heterocycles into your current chemotypes, or does your scaffold strategy lean more toward nitrogen-based rings? Explore our range of building blocks using the advanced search tools at https://lnkd.in/eVbfw6Ua To read more about Oxolanes in drug discovery, take a look at the following interesting papers: 1. Tetrahydrofuran-Containing Pharmaceuticals: Targets, Pharmacological Activities, and their SAR Studies https://lnkd.in/eJ8sU\_MA 2. Role of Lewis Acids toward the Synthesis of Tetrahydrofuran Motifs: An Update https://lnkd.in/e8bcJRXg

#MedicinalChemistry #DrugDiscovery #Oxolane
LinkedIn

The 1,1'-biphenyl scaffold has a strong claim to being one of medicinal chemistry's most widely exploited privileged scaffolds

  Its therapeutic breadth is well established. Biphenyl-containing chemotypes have demonstrated activity across anti-inflammatory, antihypertensive, CNS, oncology and anti-infective applications. This versatility reflects the scaffold's ability to engage hydrophobic binding pockets through favourable dispersion interactions, aromatic contacts and shape complementarity, while peripheral substitution allows medicinal chemists to optimise potency, selectivity, solubility and metabolic stability   Perhaps its greatest commercial success has come in cardiovascular medicine. Several clinically important angiotensin II receptor blockers \(ARBs\), including losartan, irbesartan, candesartan, olmesartan and azilsartan, share a biphenyl-tetrazole pharmacophore, while valsartan retains the biphenyl core but replaces the tetrazole with a carboxylic acid. Approved in 1995 and 1996 respectively, losartan and valsartan remain standards of care decades later. The longevity of this chemotype reflects the combination of high AT1 receptor affinity with favourable pharmacokinetic properties.   Anti-infective research continues to generate promising biphenyl-based leads. Optimised derivatives have demonstrated activity against resistant Candida species and mutant variants of HIV-1 reverse transcriptase and protease in preclinical studies. Strategic structural modifications, including selective halogen substitution and conformational control through steric design, can improve metabolic stability by reducing susceptibility to oxidative metabolism while influencing preferred bioactive conformations, ultimately supporting improved pharmacokinetic performance   Atropisomerism has added another dimension that medicinal chemists are increasingly exploiting rather than avoiding. Class-2 atropisomers, with intermediate rotational barriers that racemise over minutes to months, earned the "lurking menace" label because their stereochemistry can complicate characterisation and development. In contrast, Class-3 atropisomers are configurationally stable and can be isolated as single atropisomers, allowing conformational restriction to improve target selectivity in appropriately designed systems, particularly for kinase inhibitors. The shift from viewing atropisomerism as a liability to treating it as a deliberate design strategy is now well underway   Explore our range of 1,1'-biphenyl scaffolds using the advanced search tools at https://lnkd.in/eVbfw6Ua To read more, take a look at the following interesting papers: 1. Biphenyl as a privileged structure in medicinal chemistry: advances in anti-infective drug discovery https://lnkd.in/edrYwC8q 2.Isolation, synthesis and medicinal chemistry of biphenyl analogs – A review. https://lnkd.in/eau6Aiy9

#MedicinalChemistry #DrugDiscovery #ActivateScientific
LinkedIn Follow Activate Scientific Arrow